484 related articles for article (PubMed ID: 19767782)
1. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
2. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.
Lim ZY; Pearce L; Ho AY; Barber L; Ingram W; Usai M; Tobal K; Devereux S; Pagliuca A; Mufti GJ
Br J Haematol; 2007 Aug; 138(4):517-26. PubMed ID: 17608767
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Lim ZY; Ho AY; Ingram W; Kenyon M; Pearce L; Czepulkowski B; Devereux S; Duarte RF; Pagliuca A; Mufti GJ
Br J Haematol; 2006 Oct; 135(2):201-9. PubMed ID: 16939494
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
5. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
van Besien K; Artz A; Smith S; Cao D; Rich S; Godley L; Jones D; Del Cerro P; Bennett D; Casey B; Odenike O; Thirman M; Daugherty C; Wickrema A; Zimmerman T; Larson RA; Stock W
J Clin Oncol; 2005 Aug; 23(24):5728-38. PubMed ID: 16009946
[TBL] [Abstract][Full Text] [Related]
9. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.
Malladi RK; Peniket AJ; Littlewood TJ; Towlson KE; Pearce R; Yin J; Cavenagh JD; Craddock C; Orchard KH; Olavarria E; McQuaker G; Collin M; Marks DI;
Bone Marrow Transplant; 2009 May; 43(9):709-15. PubMed ID: 19029965
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
13. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
14. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
15. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
16. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation.
Khabori MA; El-Emary M; Xu W; Guyatt G; Galal A; Kuruvilla J; Lipton J; Messner H; Gupta V
Bone Marrow Transplant; 2011 Apr; 46(4):516-22. PubMed ID: 20622907
[TBL] [Abstract][Full Text] [Related]
17. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
18. Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.
Shimoni A; Shem-Tov N; Volchek Y; Danylesko I; Yerushalmi R; Nagler A
Bone Marrow Transplant; 2012 Oct; 47(10):1274-82. PubMed ID: 22327135
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
Pollyea DA; Artz AS; Stock W; Daugherty C; Godley L; Odenike OM; Rich E; Smith SM; Zimmerman T; Zhang Y; Huo D; Larson R; van Besien K
Bone Marrow Transplant; 2007 Dec; 40(11):1027-32. PubMed ID: 17846595
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Lim Z; Brand R; Martino R; van Biezen A; Finke J; Bacigalupo A; Beelen D; Devergie A; Alessandrino E; Willemze R; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; Kroger N; Mufti GJ; De Witte TM
J Clin Oncol; 2010 Jan; 28(3):405-11. PubMed ID: 20008642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
